Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus ORALONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus ORALONE.
CORTENEMA vs ORALONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
ORALONE is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory cytokines.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
0.3-0.6 mg/kg IV/IM every 4-6 hours as needed; maximum single dose 30 mg.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
1.5–3 hours (mean 2.5 hours) in adults; prolonged to 3–6 hours in hepatic impairment and up to 4 hours in elderly patients.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal: >90% as glucuronide conjugates and unchanged drug (approximately 60% as metabolites, 30% unchanged). Biliary/fecal: <5%.
Category C
Category C
Corticosteroid
Corticosteroid